Tamoxifen inhibits prolactin signal transduction in ER - NOG-8 mammary epithelial cells

Cancer Letters

Volumn 116, Issue 1, 1997, Pages 41-46

  Das, Rina ^a   Vonderhaar, Barbara K ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antilactogen; Prolactin; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROTEIN KINASE; RAF PROTEIN; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CELL GROWTH; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY GLANDS, ANIMAL; MAP KINASE KINASE 1; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROLACTIN; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

ANIMALIA;

EID: 0030923920     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)04750-2     Document Type: Article

References (27)

1. Ginsburg, E. and Vonderhaar, B.K. (1995) Prolactin synthesis and secretion by human breast cancer cells, Cancer Res., 55, 2591-2595.
2. Ginsburg, E. and Vonderhaar, B.K. (1997) Prolactin: an autocrine growth factor in the mammary gland. In: Biological Signalling in the Mammary Gland, in press. Editors: C.J. Wilde and M. Peaker. Ayr, Scotland, UK.
3. Bonneterre, J., Peyrat, J.P., Vandewalle, B., Beuscart, R., Vie, M.C. and Cappelaere, P. (1982) Prolactin receptors in human breast cancer, Eur. J. Cancer Clin. Oncol., 18, 1157-1162.
4. Banerjee, R., Ginsburg, E. and Vonderhaar, B.K. (1993) Characterization of a monoclonal antibody against human prolactin receptors, Int. J. Cancer, 55, 712-721.
5. Jordan, V.C. (1995) Tamoxifen for breast cancer prevention, Proc. Soc. Exp. Biol. Med., 208, 144-149.
6. Biswas, R. and Vonderhaar, B.K. (1989) Antiestrogen inhibition of prolactin induced growth of the Nb2 rat lymphoma cell line, Cancer Res., 49, 6295-6299.
7. Banerjee, R., Biswas, R. and Vonderhaar, B.K. (1993) Characteristics of a membrane-associated antilactogen binding site for tamoxifen, Mol. Cell. Endocrinol., 98, 1-8.
8. Das, R. and Vonderhaar, B.K. (1996) Involvement of SHC, Grb2, Sos and ras in prolactin signal transduction in mammary cells, Oncogene, 13, 1139-1145.
9. Das, R. and Vonderhaar, B.K. (1996) Activation of raf-1, MEK and MAP kinase in prolactin responsive mammary cells, Breast Cancer Res. Treat., 40, 141-149.
10. Biswas, R. and Vonderhaar, B.K. (1991) Tamoxifen inhibition of prolactin action in the mouse mammary gland, Endocrinology, 128, 532-538.
11. Owens, R.B., Smith, H.S. and Hackett, A.J. (1974) Epithelial cell culture from glandular tissue of mice, J. Natl. Cancer Inst., 53, 261-266.
12. Biswas, R. and Vonderhaar, B.K. (1987) Role of serum in prolactin responsiveness of MCF-7 human breast cancer cells in long term tissue culture, Cancer Res., 47, 3509-3514.
13. Banerjee, R. and Vonderhaar, B.K. (1992) Prolactin induced protein kinase C activity in a mouse mammary epithelial cell line NOG-8, Mol. Cell. Endocrinol., 90, 61-67.
14. Das, R. and Vonderhaar, B.K. (1997) Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neoplasia, in press.
15. Berlanga, J.J., Vara, J.A.F., Martin-Perez, J. and Garcia-Ruiz, J.P. (1995) Prolactin receptor is associated with c-src kinase in rat liver, Mol. Endocrinol., 9, 1461-1467.
16. Clevenger, C.V. and Medaglia, M.V. (1994) The protein tyrosine kinase pS9fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes, Mol. Endocrinol., 8, 674-681.
17. Clevenger, C.V., Torigoe, T. and Reed, J.C. (1994) Prolactin induces rapid phosphorylation and activation of prolactin receptor-associated RAF-1 kinase in a T-cell line, J. Biol. Chem., 269, 5559-5565.
18. Croxtall, J.D., Emmas, C., White, J.O., Choudhary, Q. and Flower, R.J. (1994) Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells, Biochem. Pharmacol., 47, 197-202.
19. Jordan, V.C. (1994) Molecular mechanisms of antiestrogen action in breast cancer, Breast Cancer Res. Treat., 31, 41-52.
20. Lissoni, P., Ardizzoia, A., Barni, S., Paolorossi, F., Tancini, G., Meregalli, S., Esposti, D., Zubelewicz, B. and Braczowski, R. (1995) A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast cancer patients, Oncol. Rep., 2, 871-873.
21. Lam, H.Y.P. (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase, Biochem. Biophys. Res. Commun., 118, 27-32.
22. O'Brian, C.A., Liskamp, R.M., Solomon, D.H. and Weinstein, I.B. (1985) Inhibition of protein kinase C by tamoxifen, Cancer Res., 45, 2462-2465.
23. Vonderhaar, B.K. and Banerjee, R. (1991) Is tamoxifen also an anti-lactogen?, Mol. Cell. Endocrinol., 79, C159-C163.
24. Morgan, K., Cooke, E., Hallet, M.B. and Mansel, R.E. (1986) Inhibition of protein kinase C mediated signal transduction by tamoxifen, Biochem. Pharmacol., 35, 4463-4465.
25. Gundimeda, U., Chen, Z.-H. and Gopalakrishna, R. (1996) Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells, J. Biol. Chem., 271, 13504-13514.
26. Gallego, C., Gupta, S.K., Heasley, L.E., Qian, N.X. and Johnson, G.L. (1992) Mitogen activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat la cells, Proc. Natl. Acad. Sci. USA, 89, 7355-7359.
27. Pages, G., Lenormand, P., L'Allemain, G., Chambard, J.C., Meloche, S. and Pouyssegur, J. (1993) Mitogen-activated protein kinases p42maPk and p44maPk are required for fibroblast proliferation, Proc. Natl. Acad. Sci. USA, 90, 8319-8323.